Nicole Houston

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

Jung Min Lee, Ashley Cimino‐Mathews, Cody J. Peer et al. · Journal of Clinical Oncology · 2017 · 240 citations

Medicine, Oncology, Pharmacology +17

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

Christina M. Annunziata, Elise C. Kohn, Patricia LoRusso et al. · Investigational New Drugs · 2012 · 117 citations · Full text

Pharmacy, Oncology, Pharmacology +16

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Alexandra S. Zimmer, E. Hitt Nichols, Ashley Cimino‐Mathews et al. · Journal for ImmunoTherapy of Cancer · 2019 · 112 citations · Full text

Medicine, Oncology, Pharmacology +17

Pharmacodynamic markers and clinical results from the phase 2 study of the <scp>SMAC</scp> mimetic birinapant in women with relapsed platinum‐resistant or ‐refractory epithelial ovarian cancer

Anne M. Noonan, Kristen Bunch, Jin‐Qiu Chen et al. · Cancer · 2015 · 106 citations · Full text

Medicine, Oncology, Pharmacology +17

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions

D H Moon, Anne M. Noonan, Christina M. Annunziata et al. · British Journal of Cancer · 2013 · 68 citations · Full text

Medicine, Gynecology, Oncology +16